Explore the Agenda
7:00 am Doors Open for Registration, & Pre-Event Networking
7:40 am Organizer Opening Remarks
Drugging the Undruggable
How are Collaborations Advancing Clinical Translation of Induced Proximity
7:45 am Pharma Icebreaker Panel Discussion:
- What new capabilities are pharma looking for from a partnership? Are platform deals of interest?
- Glues, bifunctionals, antibody-degrader conjugates: what are the considerations when discussing these technologies? What evidence would make a DAC asset “partnerable”?
- Are there unique challenges when discussing degradation within large pharma that you don’t see when modalities have more clinical validation?
8:15 am Short Comfort Break to Arrange Organized Networking Session
8:30 am Pharma Icebreaker Tables: Unlocking Unmatched Meetings
- The pharma icebreaker tables running in each track create introductions between biotech and pharma
- Two weeks out from the conference, pharma will review attending biotech and biotech will review attending pharma, with both making selection to meet with companies they haven’t scheduled meetings with yet through the One-to-One Partnering Portal
- With these selections, we will build a schedule of company rotations through each pharma’s table
- Join three tables, led by three pharma, for 30 minutes each. Mixed groups rather than 1-2-1s, hear how your peers pitch themselves whilst also getting facetime with pharma yourself, first thing on day one
10:30 am Morning Break & Networking Opportunity
10:30 am One-to-One Partnering Meetings Scheduled
Meeting acceptance rate is a key KPI for a conference’s productivity. To ensure this is as high as possible the one-to-one partnering system will open 3 weeks’ from the event start.
Search the full attendee list, personalise your outreach and fill your one-to-one schedule ahead of the meeting so you can prepare.
Where do DACs fit in 2026/27 Portfolios? From Preclinical Promise to First-in-Human
11:40 am Increasing the Therapeutic Index of a Small Molecule as Precision ADCs: What Have we Learnt so Far?
- Designing DACs to be a more targeted to oncogenic drivers versus traditional small molecule inhibitors
- Discussing initial proof-of-concept case studies for DACs
- Collaboration potential between antibody engineering and protein degradation companies
ADCs, TCEs & BsAbs in Oncology
Opinions & Deal Trends Following Best-in-Class Opportunity
7:45 am Pharma Icebreaker Panel Discussion
- Understanding what it takes for pharma to invest. What are the current budgetary considerations within pharma?
- How is pharma assessing novel technologies, and where do they place within portfolios?
- What feels differentiated in a crowded space? From pharma’s perspective, what will make something best-in-class?
8:15 am Short Comfort Break to Arrange Organized Networking Session
8:30 am Pharma Icebreaker Tables: Accelerating Connections
- The pharma icebreaker tables running in each track create introductions between biotech and pharma
- Two weeks out from the conference, pharma will review attending biotech and biotech will review attending pharma, with both making selection to meet with companies they haven’t scheduled meetings with yet through the One-to-One Partnering Portal
- With these selections, we will build a schedule of company rotations through each pharma’s table
- Join three tables, led by three pharma, for 30 minutes each. Mixed groups rather than 1-2-1s, hear how your peers pitch themselves whilst also getting facetime with pharma yourself, first thing on day one
10:30 am Morning Break & Networking Opportunity
10:30 am One-to-One Partnering Meetings Scheduled
Meeting acceptance rate is a key KPI for a conference’s productivity. To ensure this is as high as possible the one-to-one partnering system will open 3 weeks’ from the event start.
Search the full attendee list, personalise your outreach and fill your one-to-one schedule ahead of the meeting so you can prepare.
Is on-Target Toxicity the Bad Thing? The Balance Between Efficacy from Drug Design & Worsening Toxicity
11:40 am Tumor Selectivity Strategies Across Multispecifics, TCEs, & ADCs: What Have we Learnt so Far?
- Engineering conditional activation through masking and pre-dosing in TCEs and ADCs
- Discussing dual-target and multispecific approaches
- Applying induced proximity to ADC specificity to substantially change the behaviour of an ADC
TCEs, BsAbs & in vivo CAR-T in Autoimmunity
From Fear of Better to Fear of Missing out in Autoimmunity
7:45 am Pharma Icebreaker Panel Discussion:
- Comparing sentiment towards immunology deal-making. Which stage of development is most appealing?
- What are the starting points, from a data package perspective, when it comes to assessing engagers or in vivo CAR-T? When evaluating an early-stage what level of data—whether safety, biomarkers, or efficacy—provides you with conviction that the program has true drug potential?
- Which diseases do you think are most promising for B-cell targeted therapies?
8:15 am Short Comfort Break to Arrange Organized Networking Session
8:30 am Pharma Icebreaker Tables: Introductions with Pharma
- The pharma icebreaker tables running in each track create introductions between biotech and pharma
- Two weeks out from the conference, pharma will review attending biotech and biotech will review attending pharma, with both making selection to meet with companies they haven’t scheduled meetings with yet through the One-to-One Partnering Portal
- With these selections, we will build a schedule of company rotations through each pharma’s table
- Join three tables, led by three pharma, for 30 minutes each. Mixed groups rather than 1-2-1s, hear how your peers pitch themselves whilst also getting facetime with pharma yourself, first thing on day one
10:30 am Morning Break & Networking Opportunity
10:30 am One-to-One Partnering Meetings Scheduled
Meeting acceptance rate is a key KPI for a conference’s productivity. To ensure this is as high as possible the one-to-one partnering system will open 3 weeks’ from the event start.
Search the full attendee list, personalise your outreach and fill your one-to-one schedule ahead of the meeting so you can prepare.
In vivo CAR-T versus TCEs: Where Does the Future Land?
11:40 am Scientific, Operational & Economic Realities for Immune-Modulating Therapies: What Have we Learnt so Far?
- Pharma’s reflections on recent in vivo CAR-T deals, what data was valuable when clinical data was minimal?
- Overlapping and diverging advantages of TCEs to in vivo CAR-T, including depth and durability of response.
- Debating clinical-adjacent innovations in delivery across viral vectors and LNPs and their application in immunology versus oncology
12:20 pm Lunch Break & Networking Opportunity
12:30 pm One-to-One Partnering Meetings Scheduled
Grab some lunch ahead of more meetings across the middle of day one. Sit down more casually with other delegates for ad hoc connections or join those you’ve prearranged to meet.
1:45 pm Company Presentation Session
What is this session?
At the intersection of innovative research and business conversations, this forum facilitates the pitching of biotech pipelines and platforms to attending pharma and investors.
How does this session work?
As you register, secure one of the 15-minute presentation slots available in this presentation session and
position your differentiation as part of the conference line-up. We will add your talk to this brochure and on our
website to showcase your differentiation in the best light and share your corporate summary with all attendees
as part of pre- and post-event content, to drive interest and follow-up in your session.
Who can present?
Those developing in-house pipeline or platform technology, without any additional service provider capabilities,
such as contract research or manufacturing.
1:45 pm Presentation Session One: Showcase Your Science
Present your company’s slides by securing a 15-minute presentation slot in front of the attending audience, within this track.
1:45 pm Presentation Session One: Showcase Your Science
Present your company’s slides by securing a 15-minute presentation slot in front of the attending audience, within this track.
1:45 pm Presentation Session One: Showcase Your Science
Present your company’s slides by securing a 15-minute presentation slot in front of the attending audience, within this track.
3:30 pm Afternoon Break & Networking Opportunity
3:30 pm One-to-One Partnering Meetings Scheduled
4:40 pm 2025/26 Deal-Making Highlights: How Did They Happen?
- Representing examples of successful deal-making and successful management of alliances to foster future deals, what are the learnings?
- Sharing how early-stage programs can successfully navigate the “show me data” barrier with pharma, and the activation barrier to licencing technologies between equal sized biotech
- Debating recent regulatory and emerging technology shifts, and how these will shape licensing deals for the discussed modalities
5:20 pm Drinks Reception
Connect more casually at the end of day one drinks reception. Enjoy an informal networking with all attending colleagues, to follow up with contacts from other partnering initiatives, catch those you haven’t already run into, and meet with old connections again in-person. Deliberately timed ahead of key events in the business development calendar, use this as an opportunity to become front-of-mind, and start conversations going into the Fall calendar.